Veraxa Biotech notifies availability of press release on BiTAC-TCE regulatory progress

VRXA•2026-07-20

AACR 2026 data cited

Veraxa referenced AACR 2026 data showing selective tumor-cell killing with improved safety signals versus a traditional TCE.

Scientific advice on BiTAC-TCE program

Veraxa Biotech received Scientific Advice from Germany’s Paul-Ehrlich-Institute on the biology and non-clinical development plan for its BiTAC-TCE program.

Feedback supports dual-targeting format

The company said the feedback supports the dual-targeting, conditionally active BiTAC-TCE format, providing early regulatory alignment ahead of clinical development.

Veraxa Biotech notifies availability of press release on BiTAC-TCE regulatory progress

AACR 2026 data cited

Scientific advice on BiTAC-TCE program

Feedback supports dual-targeting format

Related News

Eagle Point Income publishes June 2026 update; estimated NAV per share USD 12.48-12.58

Energizer to webcast fiscal Q3 results discussion

AMR Resources Acquisition issues warrants exercisable at USD 11.5 per share in IPO units

OMA completes issuance of Ps 3 billion long-term certificates in Mexico debt market

Goldman Sachs: Brent Might Rise Above $120/bbl in 2026 Q4 if Hormuz Remains Disrupted